Fulgent Genetics, Inc. ($FLGT) reported second-quarter 2026 revenue of $85.4 million, up 4.4% from a year ago, but results fell short of expectations. The company also posted a wider-than-expected loss, with diluted earnings per share of -$1.05 versus an estimate of -$0.47.
Profitability remained under pressure in the quarter. Gross profit declined to $25.7 million, while operating loss widened to -$36.1 million and net loss attributable to common shareholders came in at -$29.5 million. Cost of sales rose to $59.7 million, putting further pressure on margins.
Cash generation also remained negative, with operating cash flow of -$23.8 million. Capital spending was modest at $3.9 million, while cash and cash equivalents fell to $26.3 million. Total liabilities stood at $93.2 million.
- Revenue: $85.4 million
- Net loss: -$29.5 million
- Diluted EPS: -$1.05
- Operating cash flow: -$23.8 million
- Cash and equivalents: $26.3 million
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Fulgent Genetics, Inc. Insider Trading Activity
Fulgent Genetics, Inc. insiders have traded $FLGT stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $FLGT stock by insiders over the last 6 months:
- JIAN XIE (President and COO) has made 0 purchases and 2 sales selling 3,347 shares for an estimated $59,519.
- HANLIN GAO (Chief Scientific Officer) has made 0 purchases and 2 sales selling 2,633 shares for an estimated $46,822.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Fulgent Genetics, Inc. Hedge Fund Activity
We have seen 68 institutional investors add shares of Fulgent Genetics, Inc. stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 1,522,021 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $24,200,133
- INVENOMIC CAPITAL MANAGEMENT LP added 610,318 shares (+inf%) to their portfolio in Q1 2026, for an estimated $9,704,056
- RTW INVESTMENTS, LP added 583,973 shares (+82.8%) to their portfolio in Q1 2026, for an estimated $9,285,170
- MILLENNIUM MANAGEMENT LLC removed 537,556 shares (-57.2%) from their portfolio in Q1 2026, for an estimated $8,547,140
- JACOBS LEVY EQUITY MANAGEMENT, INC added 356,359 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,666,108
- QUBE RESEARCH & TECHNOLOGIES LTD removed 286,511 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $4,555,524
- POINT72 ASSET MANAGEMENT, L.P. removed 236,954 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $3,767,568
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Fulgent Genetics, Inc. Government Contracts
We have seen $6,923,000 of award payments to $FLGT over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- IDIQ, GERMLINE GENETIC TESTING SERVICES FOR VETERANS HEALTH ADMINSTRATION NATIONAL ONOCOLOGY PROGRAM (NOP),...: $6,573,600
- GENETICS TESTING: $200,000
- GERMLINE PGX MOLECULAR TESTING: $100,000
- GENETIC TESTING FOR VA PORTLAND HEALTH CARE SYSTEM: $49,400
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
